http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Ryo Ikeda (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Yuji Ikeda,Akiko Furusawa,Ryo Kitagawa,Aya Tokinaga,Fuminori Ito,Masayo Ukita,Hidetaka Nomura,Wataru Yamagami,Hiroshi Tanabe,Mikio Mikami,Nobuhiro Takeshima,Nobuo Yaegashi 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.3
Objective: Although radiation therapy (RT) and concurrent chemoradiotherapy (CCRT)are the global standards for adjuvant therapy treatment in cervical cancer, many Japaneseinstitutions choose chemotherapy (CT) because of the low frequency of irreversible adverseevents. In this study, we aimed to clarify the trends of adjuvant therapy for intermediate/highriskcervical cancer after radical surgery in Japan. Methods: A questionnaire survey was conducted by the Japanese Gynecologic OncologyGroup to 186 authorized institutions active in the treatment of gynecologic cancer. Results: Responses were obtained from 129 facilities. Adjuvant RT/CCRT and intensitymodulatedRT were performed in 98 (76%) and 23 (18%) institutions, respectively. On theother hand, CT was chosen as an alternative in 93 institutions (72%). The most commonregimen of CT, which was used in 66 institutions (51%), was a combination of cisplatin/carboplatin with paclitaxel. CT was considered an appropriate alternative option to RT/CCRTin patients with risk factors such as bulky tumors, lymph node metastasis, lymphovascularinvasion, parametrial invasion, and stromal invasion. The risk of severe adverse events wasconsidered to be lower for CT than for RT/CCRT in 109 institutions (84%). Conclusion: This survey revealed a variety of policies regarding adjuvant therapy amonginstitutions. A clinical study to assess the efficacy or non-inferiority of adjuvant CT iswarranted.
-
Two Step Framework to Extend Workflow Nets and Soundizability Problem
Shingo Yamaguchi,Ryo Ikeda,Minoru Tanaka 대한전자공학회 2009 ITC-CSCC :International Technical Conference on Ci Vol.2009 No.7
We discuss in this paper whether we can extend work-flow nets (WF-nets for short) under the condition to preserve behavioral inheritance and soundness. We propose a two step framework to extend WF-nets, i.e. we first extend a given WF-net under the condition to preserve only behavioral inheritance, and then correct it to be sound if necessary. We tackle a problem of deciding whether we can correct an unsound WF-net to be sound under the condition to preserve behavioral inheritance, named soundizability problem. There are two kinds of behavioral inheritance: Projection inheritance and protocol inheritance. Our results show that if an acyclic free choice WF-net is extended under the condition to preserve projection inheritance, the extended WF-net is sound; If an acyclic free choice WF-net is extended under the condition to preserve protocol inheritance, the extended WF-net may be unsound; The unsound extended WF-net cannot be corrected to be sound under the condition to preserve projection inheritance, but may be corrected under the condition to preserve protocol inheritance.
-
Serum Periplakin as a Potential Biomarker for Urothelial Carcinoma of the Urinary Bladder
Matsumoto, Kazumasa,Ikeda, Masaomi,Matsumoto, Toshihide,Nagashio, Ryo,Nishimori, Takanori,Tomonaga, Takeshi,Nomura, Fumio,Sato, Yuichi,Kitasato, Hidero,Iwamura, Masatsugu Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.22
The objectives of this study were to examine serum periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum periplakin was performed in 50 patients and 30 normal controls with anti-periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p<0.0001). The area under the receiver-operator curve level for urothelial carcinoma of the urinary bladder was 0.845. The sensitivity and specificity, using a cut-off point of 4.045, were 83.7% and 73.3%, respectively. In addition, serum periplakin levels were significantly higher in patients with muscle-invasive cancer than in those with nonmuscle-invasive cancer (P = 0.03). In multivariate Cox proportional hazards regression analysis, none of the clinicopathological factors was associated with an increased risk for progression and cancer-specific survival. Examination of the serum periplakin level may play a role as a non-invasive diagnostic modality to aid urine cytology and cystoscopy.
-
Tsumura, Hideyasu,Matsumoto, Kazumasa,Ikeda, Masaomi,Yanagita, Kengo,Hirano, Shuhei,Hagiwara, Masahiro,Nagashio, Ryo,Fujita, Tetsuo,Sato, Yuichi,Iwamura, Masatsugu Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.4
Background: Uroplakins have been widely investigated as potential markers in patients with bladder cancer because these proteins are specific to the urothelium. However, the role of uroplakin proteins in bladder cancer remains unknown. In this study, preoperative serum levels of uroplakin III were measured in patients with urothelial carcinoma of the urinary bladder and examined for possible association with clinicopathological features and clinical outcomes. Materials and Methods: This study included 52 bladder cancer patients at various stages and 28 healthy controls. Uroplakin III levels were detected in preoperative sera using an automated dot blot system and a micro-dot blot array. Results: There was a significant increase in serum uroplakin III levels in patients with bladder cancer as compared to healthy controls (p<0.05). In addition, serum uroplakin III levels were associated with muscle-invasive status, high grade and lymphovascular invasion (p<0.02). Log-rank tests indicated high serum uroplakin III to be significantly associated with cancer-specific mortality. Conclusions: Determination of serum uroplakin III level could be valuable for identifying patients with biologically aggressive bladder cancer.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
